Clinical Trial

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Protocol Amendment History 4 changes
notable Trial sites expanded: 77 -> 100 locations 2026-07-01
critical Recruitment opened 2026-05-16
notable Trial sites expanded: 30 -> 77 locations 2026-05-16
notable Trial sites expanded: 0 -> 30 locations 2026-04-09
Trial Details
NCT Number NCT07415031
Lead Sponsor Mirati Therapeutics Inc.
Conditions Solid Tumors
Enrollment 170 participants
Start Date 2026-05-06
Primary Completion 2028-02-16 (estimated)
Study Completion 2028-02-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-27